Article
19 Apr 2024
Southeast Litigation Update: February 2024
AUTHORS CONTENT
Article
21 Sep 2023
Claim Construction Leads To Unpatentability For Lack Of Written Description Support
Article
08 Sep 2023
"Nearly All" Not Quite Good Enough To Achieve Discretionary Denial Under §325(d)
Article
12 Apr 2023
Disclaimers Can Be Held Against The Patentee
Article
17 Mar 2023
District Court Collateral Estoppel: Materially Altering The Question Of Invalidity
Article
24 Nov 2022
PTAB Denies IPR Challenging Patent Relating To A Prenatal Vitamin
Article
23 Nov 2022
Product-By-Process Construction Dooms Claims
Article
08 Nov 2022
The CCPA's Lasting Impact On U.S. Patent Law – An Examination Of CCPA Enablement Decisions
Article
05 Oct 2022
Want To Avoid Having Your Complaint Dismissed? Plead It With Sufficient Particularity And Don't Take Positions Contrary To What You Told PTAB
Article
22 Sep 2022
PTAB Invalidates United Therapeutics Patent Relating To The Hypertension Drug - Tyvaso®
Article
20 Sep 2022
USPTO Director Initiates Sua Sponte Review To Address Timing Of Finitiv Factor 4 Stipulation
Article
01 Sep 2022
USPTO Refusal To Accept Requests For Director Review Of Institution Decisions Not An Appointments Clause Violation
Article
02 Aug 2022
When "Good Enough" Is Good Enough For Finding Obviousness
Article
27 Jul 2022
Past Its Peak: Freedom To Operate, Inc. Fails To Persuade PTAB To Institute Two Post-Grant Reviews For Patents Covering Psilocybin
Article
26 May 2022
Not Crossing The Wire: Petitioner Merely "Expanded" On Previously Filed Arguments Rather Than Making "New" Arguments
Article
18 May 2022
To Err Is Human, To Forgive Divine – If There Was Error
Article
10 May 2022
Claim Components Without Amount Or Function Limitations Anticipated By Bare Disclosure
Article
25 Apr 2022
Spotted: The Rare AIA Derivation Proceeding!
Article
08 Apr 2022
How Sweet It Smells: Examiner Rejection Of Composition Claims Reversed
Article
14 Mar 2022
ANDA Specification Controls Infringement Analysis, Not Expert Testimony